Literature DB >> 35271343

The immunology and immunopathology of COVID-19.

Miriam Merad1, Catherine A Blish2, Federica Sallusto3,4, Akiko Iwasaki5,6.   

Abstract

Considerable research effort has been made worldwide to decipher the immune response triggered upon severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections, identify the drivers of severe and fatal COVID-19, and understand what leads to the prolongation of symptoms after disease resolution. We review the results of almost 2 years of COVID-19 immunology research and discuss definitive findings and remaining questions regarding our understanding of COVID-19 pathophysiology. We discuss emerging understanding of differences in immune responses seen in those with and without Long Covid syndrome, also known as post-acute sequelae of SARS-CoV-2. We hope that the knowledge gained from this COVID-19 research will be applied in studies of inflammatory processes involved in critical and chronic illnesses, which remain a major unmet need.

Entities:  

Mesh:

Substances:

Year:  2022        PMID: 35271343     DOI: 10.1126/science.abm8108

Source DB:  PubMed          Journal:  Science        ISSN: 0036-8075            Impact factor:   47.728


  40 in total

1.  Long-term neurologic outcomes of COVID-19.

Authors:  Evan Xu; Yan Xie; Ziyad Al-Aly
Journal:  Nat Med       Date:  2022-09-22       Impact factor: 87.241

2.  Buckling up against COVID-19 after CAR T-cell therapy.

Authors:  Jeffery J Auletta
Journal:  Blood       Date:  2022-07-14       Impact factor: 25.476

3.  Longitudinal Analysis of Biologic Correlates of COVID-19 Resolution: Case Report.

Authors:  Natalie Bruiners; Valentina Guerrini; Rahul Ukey; Ryan J Dikdan; Jason H Yang; Pankaj Kumar Mishra; Alberta Onyuka; Deborah Handler; Joshua Vieth; Mary Carayannopoulos; Shuang Guo; Maressa Pollen; Abraham Pinter; Sanjay Tyagi; Daniel Feingold; Claire Philipp; Steven K Libutti; Maria Laura Gennaro
Journal:  Front Med (Lausanne)       Date:  2022-06-15

Review 4.  Insights Gained Into the Treatment of COVID19 by Pulmonary Surfactant and Its Components.

Authors:  Dan Li; Xianzheng Wang; Yingzhao Liao; Shouchuan Wang; Jinjun Shan; Jianjian Ji
Journal:  Front Immunol       Date:  2022-05-03       Impact factor: 8.786

Review 5.  p53/NF-kB Balance in SARS-CoV-2 Infection: From OMICs, Genomics and Pharmacogenomics Insights to Tailored Therapeutic Perspectives (COVIDomics).

Authors:  Daniela Milani; Lorenzo Caruso; Enrico Zauli; Adi Mohammed Al Owaifeer; Paola Secchiero; Giorgio Zauli; Donato Gemmati; Veronica Tisato
Journal:  Front Pharmacol       Date:  2022-05-27       Impact factor: 5.988

6.  The IL-1β, IL-6, and TNF cytokine triad is associated with post-acute sequelae of COVID-19.

Authors:  Christoph Schultheiß; Edith Willscher; Lisa Paschold; Cornelia Gottschick; Bianca Klee; Svenja-Sibylla Henkes; Lidia Bosurgi; Jochen Dutzmann; Daniel Sedding; Thomas Frese; Matthias Girndt; Jessica I Höll; Michael Gekle; Rafael Mikolajczyk; Mascha Binder
Journal:  Cell Rep Med       Date:  2022-06-21

Review 7.  Role of the Ribonuclease ONCONASE in miRNA Biogenesis and tRNA Processing: Focus on Cancer and Viral Infections.

Authors:  Marta Menegazzi; Giovanni Gotte
Journal:  Int J Mol Sci       Date:  2022-06-12       Impact factor: 6.208

Review 8.  Surviving the Storm: Cytokine Biosignature in SARS-CoV-2 Severity Prediction.

Authors:  Rahnuma Ahmad; Mainul Haque
Journal:  Vaccines (Basel)       Date:  2022-04-14

9.  Effects of Purinergic Receptor Deletion or Pharmacologic Modulation on Pulmonary Inflammation in Mice.

Authors:  Gregory S Whitehead; Tadeusz P Karcz; Dilip K Tosh; Young-Hwan Jung; Zhiwei Wen; Ryan G Campbell; Varun Gopinatth; Zhan-Guo Gao; Kenneth A Jacobson; Donald N Cook
Journal:  ACS Pharmacol Transl Sci       Date:  2022-10-05

10.  Vaccination strategy for preventing the spread of SARS-CoV-2 in the limited supply condition: A mathematical modeling study.

Authors:  Yi-Fan Lin; Yuwei Li; Qibin Duan; Hao Lei; Dechao Tian; Shenglan Xiao; Yawen Jiang; Caijun Sun; Xiangjun Du; Yuelong Shu; Huachun Zou
Journal:  J Med Virol       Date:  2022-05-04       Impact factor: 20.693

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.